GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Operating Margin %

OmniAb (OmniAb) Operating Margin % : -593.34% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. OmniAb's Operating Income for the three months ended in Mar. 2024 was $-22.55 Mil. OmniAb's Revenue for the three months ended in Mar. 2024 was $3.80 Mil. Therefore, OmniAb's Operating Margin % for the quarter that ended in Mar. 2024 was -593.34%.

The historical rank and industry rank for OmniAb's Operating Margin % or its related term are showing as below:

OABI' s Operating Margin % Range Over the Past 10 Years
Min: -396.84   Med: -102.48   Max: -45.11
Current: -396.84


OABI's Operating Margin % is ranked worse than
62.24% of 1025 companies
in the Biotechnology industry
Industry Median: -155.93 vs OABI: -396.84

OmniAb's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

OmniAb's Operating Income for the three months ended in Mar. 2024 was $-22.55 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-83.52 Mil.


OmniAb Operating Margin % Historical Data

The historical data trend for OmniAb's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Operating Margin % Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
-71.12 -110.12 -102.48 -45.11 -203.19

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.96 -279.95 -370.91 -439.78 -593.34

Competitive Comparison of OmniAb's Operating Margin %

For the Biotechnology subindustry, OmniAb's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OmniAb's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Operating Margin % distribution charts can be found below:

* The bar in red indicates where OmniAb's Operating Margin % falls into.



OmniAb Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

OmniAb's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-69.419 / 34.164
=-203.19 %

OmniAb's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-22.553 / 3.801
=-593.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OmniAb  (NAS:OABI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


OmniAb Operating Margin % Related Terms

Thank you for viewing the detailed overview of OmniAb's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OmniAb (OmniAb) Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010

OmniAb (OmniAb) Headlines

From GuruFocus

OmniAb Announces Completion of Spin-Off and Business Combination

By Business Wire Business Wire 11-01-2022

OmniAb to Participate in Upcoming Investor Conferences in May

By Business Wire Business Wire 04-25-2023

OmniAb Launches OmniDeep� at the PEGS Boston Conference and Expo

By Business Wire Business Wire 05-17-2023

OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell

By Business Wire Business Wire 11-02-2022